Biosyngen Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
3
Biosyngen General Information
Description
Operator of an immuno-oncology company intended to focus on unmet needs of solid tumors and lymphoproliferative diseases. The company is developing chimeric antigen receptor cells targeting multiple solid tumors and lymphomas while understanding the complexity of cancer demands a targeted approach, enabling patients to get quality treatment and results for their new life.
Contact Information
Website
www.biosyngen.comCorporate Office
- Taiseng Exchange, 5 Tai Seng Avenue
- Number 08-51/52/53/54, Tower C
- Singapore, 536671
- Singapore
Corporate Office
- Taiseng Exchange, 5 Tai Seng Avenue
- Number 08-51/52/53/54, Tower C
- Singapore, 536671
- Singapore
Biosyngen Timeline
Biosyngen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 01-Dec-2023 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC | 21-Oct-2021 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC | 25-Nov-2019 | $8.82M | $8.82M | Completed | Clinical Trials - Phase 1 |
Biosyngen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Biosyngen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biosyngen Patents
Biosyngen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-11020419-B2 | Use of polyinosinic-polycytidylic acid compositions in treatment of malignant effusion | Active | 30-Sep-2016 | ||
| US-20190328767-A1 | Use of polyinosinic-polycytidylic acid compositions in treatment of malignant effusion | Active | 30-Sep-2016 | ||
| EP-3518938-A1 | Use of polyinosinic polycytidylic acid compositions in treatment of malignant effusion | Pending | 30-Sep-2016 | ||
| EP-3518938-A4 | Use of polyinosinic polycytidylic acid compositions in treatment of malignant effusion | Pending | 30-Sep-2016 | A61K31/787 |
Biosyngen Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Asia Business Group | Corporation | Minority | ||
| SCI Group (Guangzhou) | Asset Manager | Minority | ||
| Skyline Galaxy Capital | Venture Capital | Minority |
Biosyngen FAQs
-
When was Biosyngen founded?
Biosyngen was founded in 2016.
-
Where is Biosyngen headquartered?
Biosyngen is headquartered in Singapore, Singapore.
-
What industry is Biosyngen in?
Biosyngen’s primary industry is Drug Discovery.
-
Is Biosyngen a private or public company?
Biosyngen is a Private company.
-
What is Biosyngen’s current revenue?
The current revenue for Biosyngen is .
-
How much funding has Biosyngen raised over time?
Biosyngen has raised $86.3M.
-
Who are Biosyngen’s investors?
Asia Business Group, SCI Group (Guangzhou), and Skyline Galaxy Capital have invested in Biosyngen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
